{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:31:10Z","timestamp":1787164270385,"version":"build-2736575974"},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,8,1]]},"DOI":"10.2169\/internalmedicine.2865-23","type":"journal-article","created":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T17:10:59Z","timestamp":1704129059000},"page":"2187-2191","source":"Crossref","is-referenced-by-count":6,"title":["Anti-IgLON5 Disease Showing an Improvement in Dysautonomia, Including Vocal Cord Palsy, via Combined Immunotherapy"],"prefix":"10.2169","volume":"63","author":[{"given":"Daisuke","family":"Sato","sequence":"first","affiliation":[{"name":"Division of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Kondo","sequence":"additional","affiliation":[{"name":"Division of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Igari","sequence":"additional","affiliation":[{"name":"Division of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chifumi","family":"Iseki","sequence":"additional","affiliation":[{"name":"Division of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Kawahara","sequence":"additional","affiliation":[{"name":"Division of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Yamagata University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoya","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Neurology, Gifu University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Neurology, Gifu University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Shimohata","sequence":"additional","affiliation":[{"name":"Department of Neurology, Gifu University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Ohta","sequence":"additional","affiliation":[{"name":"Division of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Gaig C, Graus F, Compta Y, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology 88: 1736-1743, 2017.","DOI":"10.1212\/WNL.0000000000003887"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Honorat JA, Komorowski L, Josephs KA, et al. IgLON5 antibody: neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm 4: e385, 2017.","DOI":"10.1212\/NXI.0000000000000385"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Fuseya K, Kimura A, Yoshikura N, Yamada M, Hayashi Y, Shimohata T. Corticobasal syndrome in a patient with anti-IgLON5 antibodies. Mov Disord Clin Pract 7: 557-559, 2020.","DOI":"10.1002\/mdc3.12957"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Werner J, Jelcic I, Schwarz EI, et al. Anti-IgLON5 disease: a new bulbar-onset motor neuron mimic syndrome. Neurol Neuroimmunol Neuroinflamm 8: e962, 2021.","DOI":"10.1212\/NXI.0000000000000962"},{"key":"5","unstructured":"5. Gaig C, Compta Y, Heidbreder A, et al. Frequency and characterization of movement disorders in anti-IgLON5 disease. Neurology 97: e1367-e1381, 2021."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Cabezudo-Garcia P, Mena-Vazquez N, Estivill Torrus G, Serrano-Castro P. Response to immunotherapy in anti-IgLON5 disease: a systematic review. Acta Neurol Scand 141: 263-270, 2020.","DOI":"10.1111\/ane.13207"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Schroder JB, Melzer N, Ruck T, et al. Isolated dysphagia as initial sign of anti-IgLON5 syndrome. Neurol Neuroimmunol Neuroinflamm 4: e302, 2017.","DOI":"10.1212\/NXI.0000000000000302"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Nissen MS, Blaabjerg M. Anti-IgLON5 disease: a case with 11-year clinical course and review of the literature. Front Neurol 10: 1056, 2019.","DOI":"10.3389\/fneur.2019.01056"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Grossauer A, Hussl A, Mahlknecht P, et al. Anti-IgLON5 disease with isolated hemichorea: a case report and review of the literature. Mov Disord Clin Pract 10: 115-119, 2023.","DOI":"10.1002\/mdc3.13614"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sabater L, Planaguma J, Dalmau J, Graus F. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflammation 13: 226, 2016.","DOI":"10.1186\/s12974-016-0689-1"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Landa J, Gaig C, Plaguma J, et al. Effects of IgLON5 antibodies on neuronal cytoskeleton: a link between autoimmunity and neurodegeneration. Ann Neurol 88: 1023-1027, 2020.","DOI":"10.1002\/ana.25857"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ryding M, Gamre M, Nissen MS, et al. Neurodegeneration induced by anti-IgLON5 antibodies studied in induced pluripotent stem cell-derived human neurons. Cells 10: 837, 2021.","DOI":"10.3390\/cells10040837"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Gelpi E, Hoftberger R, Graus F, et al. Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol 132: 531-543, 2016.","DOI":"10.1007\/s00401-016-1591-8"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Chen AL, Riley DE, King SA, et al. The disturbance of gaze in progressive supranuclear palsy: implications for pathogenesis. Front Neurol 1: 147, 2010.","DOI":"10.3389\/fneur.2010.00147"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Phokaewvarangkul O, Bhidayasiri R. How to spot ocular abnormalities in progressive supranuclear palsy? A practical review. Transl Neurodegener 8: 20, 2019.","DOI":"10.1186\/s40035-019-0160-1"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Baizabal-Carvallo JF, Cardoso F, Jankovic J. Myorhythmia: phenomenology, etiology, and treatment. Mov Disord 30: 171-179, 2015.","DOI":"10.1002\/mds.26093"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Asioli GM, Calandra-Buonaura G, Mastrangelo V, et al. Persistence of facio-skeletal myorhythmia during sleep in anti-IgLON5 disease. Mov Disord Clin Pract 8: 460-463, 2021.","DOI":"10.1002\/mdc3.13159"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Zoccal DB, Furuya WI, Bassi M, Colombari DS, Colombari E. The nucleus of the solitary tract and the coordination of respiratory and sympathetic activities. Front Physiol 5: 238, 2014.","DOI":"10.3389\/fphys.2014.00238"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Brunetti V, Della Marca G, Spagni G, et al. Immunotherapy improves sleep and cognitive impairment in anti-IgLON5 encephalopathy. Neurol Neuroimmunol Neuroinflamm 6: e577, 2019.","DOI":"10.1212\/NXI.0000000000000577"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Zhang YH, Ni Y, Gao YN, et al. Anti-IgLON5 disease: a novel topic beyond neuroimmunology. Neural Regen Res 18: 1017-1022, 2023.","DOI":"10.4103\/1673-5374.355742"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/15\/63_2865-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T23:42:01Z","timestamp":1722642121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/15\/63_2865-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":20,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2865-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"article-number":"2865-23"}}